In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.

“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”

“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”

Join host, Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.

The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.

Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

CEO INTERVIEW: AnnovisBio, Inc. ($ANVS) gets FDA green light to initiate Phase 3 Alzheimer's study

Powered by Wave AI